###begin article-title 0
APOBEC3G levels predict rates of progression to AIDS
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 103 111 103 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 158 166 158 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 234 241 234 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 154 157 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 213 216 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 286 291 <span type="species:ncbi:9606">human</span>
###xml 319 322 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 335 338 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 451 454 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 537 540 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 623 626 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 678 681 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 910 917 <span type="species:ncbi:9606">patient</span>
APOBEC3G (hA3G) is a newly discovered cellular factor of innate immunity that inhibits HIV replication in vitro. Whether hA3G conferrs protection against HIV in vivo is not known. To investigate the possible anti-HIV activity of hA3G in vivo, we examined hA3G mRNA abundance in primary human cells isolated from either HIV-infected or HIV-uninfected individuals, and found that hA3G mRNA levels follow a hierarchical order of long-term nonprogressors>HIV-uninfected>Progressors; and, hA3G mRNA abundance is correlated with surrogates of HIV disease progression: viral load and CD4 count. Another group later confirmed that HIV-infected subjects have lower hA3G mRNA levels than HIV-uninfected controls, but did not find correlations between hA3G mRNA levels and viral load or CD4 count. These conflicing results indicate that a more comprehensive, conclusive investigation of hA3G expression levels in various patient cohorts is urgently needed.
###end p 3
###begin title 4
Presentation of the hypothesis
###end title 4
###begin p 5
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 53 56 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 447 450 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
For exploring whether hA3G abundance might influence HIV disease progression, we have formulated a hypothesis that inlcudes two parts: a) in vivo, the basal hA3G mRNA expression level per PBMC is a constant - with minor physiologic fluctuations - determined by host genetic and epigenetic elements in a healthy individual; and that the basal hA3G mRNA expression levels in a population follow a Normal (or Gaussian) distribution; b) that although HIV infects randomly, it results in more rapid disease progression in those with lower hA3G mRNA levels, and slower disease progression in those with higher hA3G mRNA levels.
###end p 5
###begin title 6
Testing the hypothesis
###end title 6
###begin p 7
###xml 122 125 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 169 172 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
This hypothesis could be tested by a straighforward set of experiments to compare the distribution of hA3G mRNA levels in HIV-uninfected healthy individuals and that in HIV-infected, antiretroviral therapy-naive subjects who are at early and late stages of infection.
###end p 7
###begin title 8
Implication of the hypothesis
###end title 8
###begin p 9
###xml 285 288 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
Testing this hypothesis will have significant implications for biomedical research. a) It will link hA3G to the mechanisms underlying slower disease progression in long-term nonprogressors. And, b) It may help to establiseh a new prognostic marker, the hA3G abundance measurement, for HIV-infected patients.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 669 670 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 47 50 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 334 337 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 527 530 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
In the absence of antiretroviral therapy, most HIV-infected individuals die of AIDS within 8-10 years of infection. Some of them, however, have a substantially slower rate of disease progression and have been categorized as long term nonprogressors (LTNPs), who are usually clinically asymptomatic, and having high CD4 counts and low HIV viremia levels [1]. These LTNPs offered unique opportunities to study correlates of protective immunity. Potential protective mechanisms in LTNPs include infection by defective or less fit HIV variants, having strong host immune responses, and possession of unique host genetic elements including CCR5 genotype and HLA haplotypes [1-19]. Current consensus is that each known factor only plays some degree of protection, and unknown protective host factors may yet to be discovered.
###end p 11
###begin p 12
###xml 185 194 185 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 759 768 759 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 891 899 891 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1348 1350 1348 1350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 169 172 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 324 327 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 534 537 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 539 556 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 558 561 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 567 588 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 590 593 <span type="species:ncbi:11786">MLV</span>
###xml 1286 1289 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15, or hA3G) is a novel cellular factor of innate immunity that inhibits HIV replication in vitro by causing G to A hypermutations, and consequently reduced relative infectivity of each virus produced by infected cells [20-22]. HIV counters hA3G activity by using Vif protein to bind and target hA3G protein for enhanced degradation through proteasomal pathways [21,22]. hA3G also has antiviral activities against other viruses including SIV, hepatitis B virus (HBV) and murine leukemia virus (MLV) [23-32]. Some recent studies, however, suggest that causing G to A mutations may not be the only mechanism by which hA3G exercises its antiviral activity, at least in vitro [25,33]. Whereas others reported that hA3G induced G to A hypermutations might be a major mechanism of virological control in vivo [34]. Additionally, it was reported that the activation of peripheral blood mononuclear cell (PBMC) will modified the hA3G from a low-molecular-mass (LMM) complex to a high-molecular-mass (HMM) complex, thus abrogating its antiviral effect. It was also suggested that in addition to the known mechanism of making G to A hypermutations, the LMM hA3G might exert post-entry restriction of HIV replication in resting primary CD4+T cells and monocytes [35].
###end p 12
###begin p 13
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 138 143 <span type="species:ncbi:9606">human</span>
###xml 242 245 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Overall, there is currently a relative paucity of human research data. We propose a hypothesis that reconciles these published data using human cells [34,36,37]. Testing this hypothesis will have implications for a better undersanding of the HIV pathogenesis; the development of a new diagnostic tool; as wells as providing scientific basis for the therapeutic strategy that targets Vif protein or Vif-hA3G interections.
###end p 13
###begin title 14
Presentation of the hypothesis
###end title 14
###begin p 15
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Why is there individual variation in hA3G mRNA expression level in recent reports [36,37]? We hypothesize that in vivo, the basal hA3G mRNA expression level per PBMC is a constant - with minor physiologic fluctuations - determined by host genetic and epigenetic elements in a healthy individual; and that the basal hA3G mRNA expression levels in a population follow a Normal (or Gaussian) distribution. Figure 1 uses distribution "a" to illustrate two major features of the hypothesis: 1) the hA3G mRNA levels of most subjects concentrate around the mean value of u; and, 2) the remaining subjects have values falling on either side of the mean (as a value of "z"). The hypothesis would predict the following scenario:
###end p 15
###begin p 16
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic illustration of the hypothesis</bold>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 382 385 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 407 410 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 414 417 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 466 469 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 490 493 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 567 570 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Schematic illustration of the hypothesis. We hypothesize that in human population hA3G mRNA levels (x-axis) follow a Normal distribution that has two major characteristics: 1) the hA3G mRNA levels of most subjects concentrate around the mean value of u; and, 2) the remaining subjects have values falling on either side of the mean (as a value of "z"). Distribution "a" illustrates HIV-uninfected controls (HIV-). HIV-infected subjects could be stratified into low (HIV+ subset 1), medium (HIV+ subset 2), and high hA3G subsets based on relative hA3G mRNA abundance (HIV+ subset 3). Each group's hA3G levels still follow a Normal distribution (distribution b, c, and d, respectively).
###end p 16
###begin p 17
###xml 46 47 46 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1384 1385 1384 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 50 53 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 175 178 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 263 270 <span type="species:ncbi:9606">patient</span>
###xml 446 449 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 537 540 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 583 586 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 617 620 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
###xml 831 834 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 891 894 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 908 911 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 967 970 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 980 988 <span type="species:ncbi:9606">patients</span>
###xml 1249 1252 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1333 1336 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1346 1354 <span type="species:ncbi:9606">patients</span>
At the initial time of infection (Time 0, Fig 2), HIV randomly infects individuals with differential hA3G mRNA abundance. According to the relative hA3G mRNA abundance, these HIV-infected subjects could be stratified into low, medium, and high hA3G subsets. Each patient group's hA3G levels will still form a Normal distribution (distribution b, c, and d, respectively; Fig 1). Collectively, though, the distribution of hA3G mRNA abundance among HIV-infected and uninfected subjects will overlap initially, albeit the population size of HIV-infected will be smaller than that of the HIV-uninfected. After a period of HIV infection (Time X, Fig 2), when patients' viremia reach steady-state levels and their clinical stages become stable, there will be several testable outcomes for the distribution. If hA3G level has no effect on HIV disease progression, the distributions of hA3G level in HIV-infected and HIV-uninfected individuals will overlap because subsets of HIV-infected patients who have varying hA3G levels should have similar attrition rates. If hA3G plays a protective role, one should expect increased survival of those with higher hA3G levels, such that the overall hA3G levels will shift to the right in comparison to that of normal HIV-uninfected controls. If hA3G plays a detrimental role, then its distribution in HIV-infected patients will shift to the left (Fig. 2).
###end p 17
###begin p 18
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Testable predictions of the hypothesis</bold>
###xml 58 61 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 167 170 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 227 230 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 244 247 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 360 363 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 431 434 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 535 538 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 548 556 <span type="species:ncbi:9606">patients</span>
###xml 597 600 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Testable predictions of the hypothesis. After a period of HIV infection (at Time X), there will be three outcomes for the distribution. If hA3G level has no effect on HIV disease progression, the distributions of hA3G level in HIV-infected and HIV-uninfected individuals should overlap (No effect, middle). If hA3G plays a protective role, its distribution in HIV-infected patients will shift to the right in comparison to that of HIV-uninfected controls (Protective, right). If hA3G plays a detrimental role, then its distribution in HIV-infected patients will shift to the left in comparison to HIV-uninfected individuals (Detrimental, left).
###end p 18
###begin p 19
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W</italic>
###xml 131 134 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 339 342 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 425 428 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To generalize the hypothesis, we can designate a mean value for hA3G abundance to each subject population of interest. Let (i) the HIV-uninfected subjects maintained the same distribution (as shown in Fig 1), with a mean of u; (ii) individuals with higher hA3G mRNA abundance that are enriched for LTNPs have a mean of a; and, (iii) other HIV-infected subjects have a mean of e. Assuming the proportion of LTNP in the entire HIV-infected population is W, then we would have
###end p 19
###begin p 20
u = Wa + (1-W)e.
###end p 20
###begin p 21
###xml 544 546 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 593 595 589 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">W </italic>
###xml 261 264 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 420 423 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 510 513 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 642 645 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 697 700 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
This generalized model could be tested in studies described below in the "Testing the hypothesis" section. Our published results are in good agreement with these predictions. Specifically, in a cross-sectional study involving subjects who have been chronically HIV-infected for many years (14 +/- 4 years for LTNPs, and 8 +/- 6 years for the others), we have observed that LTNPs had much higher hA3G mRNA abundance than HIV-uninfected controls (a > u, and a > e), who had higher hA3G mRNA abundance than other HIV-infected progressors (u > e) [36]. If the number of LTNPs are very small (when W approaches 0), the mean of hA3G mRNA levels in HIV-infected progressors will be very close to that of HIV-uninfected subjects (u = e).
###end p 21
###begin p 22
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 606 608 606 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 606 608 606 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n </italic></sub>
###xml 612 614 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 628 630 628 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i </italic>
###xml 628 630 628 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>i </italic></sub>
Our central hypothesis has one assumption that the basal hA3G mRNA expression levels in healthy control individual follow a Normal distribution. This could be easily tested using the Kolmogorov-Smirnov test (K-S test), which is one of the most frequently used nonparametric tests for examining whether an underlying probability distribution differs from a hypothesized distribution derived from a relative small sample size. The K-S statistics quantifies the discrepancy (D) between the experimental data and an ideal Normal distribution using the following equations. The empirical distribution function Fn for n observations yi is defined as
###end p 22
###begin p 23

###end p 23
###begin p 24
The two one-sided K-S test statistics are given by
###end p 24
###begin p 25

###end p 25
###begin p 26
###xml 6 7 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 8 9 8 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
where F(x) is the hypothesized distribution, or another empirical distribution. The probability distributions of these two statistics do not depend on what the hypothesized distribution is, as long as it is continuous.
###end p 26
###begin p 27
It should be emphasized that because hA3G's antiviral effect is part of the innate immunity, we believe that hA3G mRNA abundance per cell is mostly genetically determined, and it does not serve as a metric for CD4+ T cell count. Therefore while the hA3G mRNA levels may serve as a predictor of the rate of disease progression, it will not be a mere surrogate of CD4+ T cell count.
###end p 27
###begin title 28
Testing the hypothesis
###end title 28
###begin p 29
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 481 483 481 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 1043 1045 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1054 1055 1050 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1122 1124 1118 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 1259 1261 1255 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D </italic>
###xml 498 501 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 516 519 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 628 631 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 745 748 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To test whether hA3G mRNA expression levels in PBMCs follow a Normal distribution in a population, it is critical to perform its measurement in a sufficient number of subjects. We used the one-sample K-S test [38] to determine the required sample size. In the K-S test statistics, D is defined as the maximum absolute difference between the empirical distribution function and the estimated cumulative distribution function. From our preliminary study [36], we calculated that the D values for the HIV-negative (N), HIV-positive progressors (P), and LTNPs are 0.23, 0.28 and 0.28, respectively. To ensure that the population of HIV-infected subjects is big enough so that it will contain subjects with hA3G mRNA abundance similar to that of the HIV-infected P and LTNP, we conservatively set the maximum absolute differences to be 0.22, 0.26 and 0.26 for the N, P and LTNP subsets, respectively. If the type I error alpha = 0.05 and a minimum power of 80%, the calculated sample sizes are 66, 41 and 41 based on the method proposed by Massey [39]. Table 1 summarizes the required sample sizes for other possible values of D and power. Conservatively, we propose a sample size of 80 subjects for each testing group, so that we can detect a small difference of D = 0.2.
###end p 29
###begin p 30
Sample size requirement for testing a normal distribution
###end p 30
###begin p 31
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 139 142 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 177 180 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 215 218 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 288 291 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 478 481 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 497 500 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The experimental plan is relatively straightforward. Based on sample size calculation, we will study the hA3G mRNA levels in a total of 80 HIV-uninfected subjects, and 80 early HIV-infected subjects. We chose early HIV infected individuals because they are chronologically closest to the HIV-uninfected population. Once hA3G mRNA levels from all subjects are determined, their overall distribution will be analyzed using one-sample K-S test [38]. The hA3G mRNA distributions of HIV-uninfected and HIV-infected subjects will then be compared.
###end p 31
###begin p 32
###xml 495 502 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 64 67 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 192 199 <span type="species:ncbi:9606">patient</span>
###xml 345 348 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 403 406 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
As a complementary approach, we will next select 80 chronically HIV-infected subjects who had been infected for more than five year without antiretroviral intervention, anticipating that this patient population had undergone selection over time by virological and host genetic factors. We expect that the population mean of hA3G levels in these HIV-infected patients shifted away from the mean value of HIV-uninfected controls. Dependent on whether hA3G plays a protective or a detrimental role in vivo, such a shift could be either to the right, or to the left.
###end p 32
###begin p 33
###xml 25 28 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 438 441 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 535 538 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To directly test whether HIV infection influences hA3G mRNA level, patients at different stages of infection will be enrolled into a highly-active antiretroviral therapy (HAART) treatment trial for 12 months. PBMC will be isolated from sequential blood samples (months 0, 3, 6 and 12) for measuring hA3G mRNA levels. It is expected that a majority of patients will be responsive to the HAART treatment that could significantly reduce the HIV viral load. If hA3G mRNA levels do not change significantly during the HAART treatment, then HIV-infection per se is unlikely to have direct impact on the hA3G expression; if they do change significantly, then the mechanisms responsible for the changes will need to be further studied.
###end p 33
###begin p 34
###xml 293 296 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 321 324 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 707 710 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
One anticipated problem is that hA3G mRNA abundance might not follow a Normal distribution. Instead, it follows either a truncated Normal distribution, or other unimodal distributions. If so, we will test an alternative hypothesis that the distributions of hA3G mRNA abundance are the same in HIV-infected subjects as in HIV-uninfected controls. According to our sample size calculation, 80 subjects from each group will give 80% power for testing the alternative hypothesis at alpha = 0.05 and effect size of 0.1 (or 10%). This alternative hypothesis, if proven to be correct, can still explain our observations, and lends support to the idea that hA3G mRNA abundance is another good prognostic marker for HIV disease progression.
###end p 34
###begin p 35
###xml 93 98 <span type="species:ncbi:9606">human</span>
###xml 375 378 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
There are pros and cons of using different cell preparation for hA3G quantification. Not all human cells express hA3G. In PBMC used for our assay, however, several major subsets that constitute 60-70% of PBMC: CD4+ T cell, CD8+ T cell and monocytes all express hA3G. Ideally, one would want to perform the assay with purified CD4+ T cells that are the major target cells for HIV infection. The problem is that all known methods for purifying cells would require several hours of manipulation: either by the negative selection method which does not give high purity; or the positive selection method which may activate cells (and thus modulate hA3G mRNA levels) through specific binding antibody used for purification. Therefore, using unperturbed PBMC for assessing hA3G mRNA level may be a good compromise, albeit not a perfect solution.
###end p 35
###begin title 36
Implications of the hypothesis
###end title 36
###begin p 37
###xml 84 87 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 312 315 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
If the hypothesis were true, it will have at least two significant implications for HIV research: a) It will elucidate an unrecognized mechanism responsible for slower disease progression in long term nonprogressors; and, b) It may help to establish a new prognostic marker, the hA3G aboundance measurement, for HIV-infected patients.
###end p 37
###begin p 38
###xml 165 173 165 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 480 482 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 586 588 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 589 591 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 17 20 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 184 187 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 452 457 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 549 554 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 578 584 <span type="species:ncbi:9606">humans</span>
###xml 676 679 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
It is clear that HIV disease progression is determined by multiple factors. Testing our hypothesis will provide proof or refutation of the idea that hA3G mRNA level in vivo influences HIV disease progression, but it will not discern whether hA3G mRNA level is an independent predictor, or it has to work in concert with other host factors. One of the new host factors is the tripartite motif protein (TRIM)5alpha, which was initially found to restrain HIV-1 infection in monkeys [40]. Some variants of TRIM5alpha conferred modest protection against HIV-1 disease progression in humans [41,42]. Nevertheless, a conclusive study to determine the influence of hA3G mRNA level on HIV disease progression is evidently needed.
###end p 38
###begin title 39
List of abbreviations used
###end title 39
###begin p 40
APOBEC3G (hA3G): apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3G; also known as CEM15, or hA3G.
###end p 40
###begin p 41
LTNP: long term nonprogressors.
###end p 41
###begin title 42
Competing interests
###end title 42
###begin p 43
The authors XJ and HW have no financial competing interests. HS is the CSO of the Oxagen, Inc., a company that develops antiviral reagents based on Vif and hA3G.
###end p 43
###begin title 44
Authors' contributions
###end title 44
###begin p 45
XJ and HS performed a pilot study which contributes to the genesis of the hypothesis proposed in the current paper. XJ conceived and drafted the initial manuscript. The mathematical/statistical aspects of the hypothesis were aided by HW. All authors contributed to revision of the draft manuscript, read and approved the final manuscript.
###end p 45
###begin article-title 46
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications
###end article-title 46
###begin article-title 47
###xml 69 104 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
###end article-title 47
###begin article-title 48
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
###end article-title 48
###begin article-title 49
###xml 50 78 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
###end article-title 49
###begin article-title 50
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage
###end article-title 50
###begin article-title 51
The influence of HLA genotype on AIDS
###end article-title 51
###begin article-title 52
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Vigorous HIV-1-specific CD4+ T cell responses associates with control of viremia
###end article-title 52
###begin article-title 53
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors
###end article-title 53
###begin article-title 54
###xml 87 90 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
###end article-title 54
###begin article-title 55
###xml 28 56 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2
###end article-title 55
###begin article-title 56
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 67 75 <span type="species:ncbi:9606">children</span>
Correlates of delayed disease progression in HIV-1-infected Kenyan children
###end article-title 56
###begin article-title 57
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation
###end article-title 57
###begin article-title 58
###xml 60 95 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection
###end article-title 58
###begin article-title 59
###xml 70 105 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Characterization of gag and pol sequences from long-term survivors of human immunodeficiency virus type 1 infection
###end article-title 59
###begin article-title 60
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility
###end article-title 60
###begin article-title 61
###xml 25 53 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Multifactorial nature of human immunodeficiency virus disease: implications for therapy
###end article-title 61
###begin article-title 62
NK cell recognition
###end article-title 62
###begin article-title 63
###xml 11 14 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Containing HIV after infection
###end article-title 63
###begin article-title 64
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Defining the protective antibody response for HIV-1
###end article-title 64
###begin article-title 65
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
###end article-title 65
###begin article-title 66
Retroviral restriction by APOBEC proteins
###end article-title 66
###begin article-title 67
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors
###end article-title 67
###begin article-title 68
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
###end article-title 68
###begin article-title 69
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif
###end article-title 69
###begin article-title 70
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
###end article-title 70
###begin article-title 71
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
###end article-title 71
###begin article-title 72
Rapid evolution of primate antiviral enzyme APOBEC3G
###end article-title 72
###begin article-title 73
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G
###end article-title 73
###begin article-title 74
Editing at the crossroad of innate and adaptive immunity
###end article-title 74
###begin article-title 75
DNA deamination mediates innate immunity to retroviral infection
###end article-title 75
###begin article-title 76
###xml 28 49 <span type="species:ncbi:11786">murine leukemia virus</span>
Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 10 13 <span type="species:ncbi:11786">MLV</span>
HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles
###end article-title 77
###begin article-title 78
Antiviral Potency of APOBEC Proteins Does Not Correlate with Cytidine Deamination
###end article-title 78
###begin article-title 79
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation
###end article-title 79
###begin article-title 80
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells
###end article-title 80
###begin article-title 81
###xml 59 87 <span type="species:ncbi:12721">human immunodeficiency virus</span>
APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia
###end article-title 81
###begin article-title 82
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count
###end article-title 82
###begin article-title 83
The Kolmogorov-Smirnov test for goodness of fit
###end article-title 83
###begin article-title 84
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
###end article-title 84
###begin article-title 85
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of common human TRIM5alpha variants in HIV-1 disease progression
###end article-title 85
###begin article-title 86
###xml 72 107 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection
###end article-title 86

